July 18, 2024
Partner Presentation

Epidiolex Case Study & Long-Term Care Outcomes

Share this page
In Partnership with
2:00pm-3:00pm EST

Epidiolex is the first and only FDA-approved cannabinoid designed specifically to address seizures associated with Lennox-Gastaut Syndrome (LGS), Dravet Syndrome, and Tuberous Sclerosis Complex (TSC).


  • Describe basic seizure management in LTC settings that care for individuals with I/DD
  • Define characteristics of LGS in children and adults
  • Review the medication Epidiolex in terms of efficacy as well as the guidelines for management of potential side effects
  • Identify the BECOME study outcomes from a non-clinical perspective of potential changes in behavior, cognition, physical attributes, and emotional changes that can be seen secondary to the initiation of Epidiolex to treat seizures


  • Nanette Wrobel, Director of Business Development, Tarrytown Expocare Pharmacy